icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
no clinical added value
EYLEA does not provide any improvement in actual benefit (level V, non-existent) compared with LUCENTIS for adults in the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO).
eNq1mF1v2jAUhu/5FVHuSRo6SjsFqo21G1KrMlq0aTeVSQ7FzLXTY5uP/fo5hG50ctTV4MvEzntOfF4/PnJ6vnpkwQJQUsG7YRIdhQHwTOSUP3TD8d1l8zQ87zXSOVmQnWlmXtRqhUHGiJTdsByNJkC4jL5fX30C8z1g2GsEqZjMIVMv5mlFWfSFyNk1Kco5QboQNA8eQc1E3g0LrTZvg1QqNFn0lgJ/yoJkkMbbN7uj8/t3u+/TuBT7D1UtAa8If7CKAnfSzDQicNUnCh4ErmvyPXbSpnIEUmjMYEjUbIhiQXPIrSGmhElwCjJd5reACwaqDGIVj+fZo3QSJ3OyGsHTwJ70BzPaVyvVPGomndZJp3XcOTpLkrZTKNxZKnsVzE/E2X3SaSdJpxMDj2HNgDhWZihQEeapJlT2X9rKUxyEp1drn1NZMLKO5rJwXSqCxAwDms3v70fKP7hDgyNm1uwffa4Zi9+Y9XgLC08ZlyzqC81VDTMuR64L0Rdcwaq+om6YU6utFynIw8n+EtyO+KGeMJq5As0gR4NU49GgnmeHQ8FHImGM/ljwjfJcLOXhGbNbU0/ZFxtMWkULzJP71tnpSdJuO2+hH8ZANafLhUZRQGzoQ+U+UBnwqdgXJ8aTdqlnRx7IjJsOR2SEQU2P03TkinHhc0vmzef+9lA1YBX9fHHnao6vGnB9u3m0StO8+6esbtD1QXJjxdrE327san976X412rkxU6qQ7+N4uVxGMyKbkphViqZ4YKrvHKP+Om8vZ3XVu1Rk9JT6pDry3lYf13322mm+b4e6/X7bCVtjKNSwRy0qJHsD5+Di8Cz+2556S3v4gh3+wmxaSaKo4L6aHD2xKu5Hf1NXfokGEDfTKa25Can1ZRpXtzC9RhqXNzC9xm+K0+Ey
EwESG1dw3x0AXseB